Long-term effect of the German Parkinson’s disease multimodal complex treatment: a clinical trial with randomized allocation - Takeaways - MDSpire

Long-term effect of the German Parkinson’s disease multimodal complex treatment: a clinical trial with randomized allocation

  • By

  • Konstantin G. Heimrich

  • Aline Schönenberg

  • Sarah Mendorf

  • Hannah M. Mühlhammer

  • Ulrike Teschner

  • Thomas Lehmann

  • Stefan Brodoehl

  • Tino Prell

  • June 4, 2026

  • 0 min

Share

  • 1

    Parkinson's disease (PD) is a prevalent neurodegenerative disorder that severely impacts patients' quality of life.

  • 2

    Germany's Parkinson's disease Multimodal Complex Treatment (PD-MCT) is a structured, multidisciplinary inpatient treatment approach.

  • 3

    In 2022, 15,303 PD-MCT procedures were conducted in Germany, but data on its effectiveness remains limited.

  • 4

    The study aimed to evaluate the long-term effects of PD-MCT on motor experiences and health-related quality of life six months post-discharge.

  • 5

    Participants were randomly assigned to short or long PD-MCT, with the primary outcome measured using the MDS-UPDRS II scale.

Original Source(s)

Long-term effect of the German Parkinson’s disease multimodal complex treatment: a clinical trial with randomized allocation

  • by Konstantin G. Heimrich, Aline Schönenberg, Sarah Mendorf, Hannah M. Mühlhammer, Ulrike Teschner, Thomas Lehmann, Stefan Brodoehl, Tino Prell

  • June 4, 2026

Related Content

Editorial: AI-powered advances in diagnosis and management of movement disorders

Complexity of fractal dimension patterns and machine learning-based classification of altered motor cortical oscillatory activity in rodent models of Parkinson disease

Study on the effects and mechanisms of rhythmic auditory stimulation on freezing of gait in Parkinson’s disease: investigation based on functional near-infrared spectroscopy (fNIRS) technology